CD39 Assay Service
●
Target
CD39
●
Description
Screening and/or profiling inhibitor compounds against CD39 activity in a biochemical assay.
●
Synonyms
ENTPD1, Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Colorimetric
●
Reference Compounds and IC50
POM1, 0.01 μM
●
Assay Principle
The CD39 Inhibitor Screening Assay is a colorimetric assay designed to measure the activity of CD39 for screening and profiling applications. The assay is performed in a 96-well format using purified CD39 enzyme, ATP, CD39 assay buffer, and colorimetric detection reagent that detects free phosphate generated in the reaction catalyzed by CD39.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
P49961
●
Background
B cell activation marker Cluster of Differentiation 39 (CD39), also known as ecto-apyrase, ATP diphosphohydrolase, ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), hydrolyzes extracellular nucleotide tri- and diphosphates into AMP in the presence of Ca2+ and Mg2+. It is an important enzyme in many biological processes, including the modulation of neural cell activities, prevention of intravascular thrombosis, and regulation of immune responses. The role of regulatory T cells (Treg) links closely to CD39/CD79, and a dysfunction in this pathway can lead to cancer progression. The use of CD39 inhibitors can prove advantageous for the treatment of pathologies where CD39/CD73 pathways play a role.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
